-
Something wrong with this record ?
Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups
P. Majek, K. Pecankova, J. Cermak, JE. Dyr,
Language English Country United States
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2013
Hindawi Publishing Open Access
from 2001-01-01
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2012-12-04
Open Access Digital Library
from 2013-01-01
CINAHL Plus with Full Text (EBSCOhost)
from 2013-01-01
Medline Complete (EBSCOhost)
from 2013-01-01
Health & Medicine (ProQuest)
from 2013
ROAD: Directory of Open Access Scholarly Resources
from 2013
PubMed
26448929
DOI
10.1155/2015/209745
Knihovny.cz E-resources
- MeSH
- Biomarkers blood MeSH
- Adult MeSH
- alpha-2-HS-Glycoprotein metabolism MeSH
- Glycoproteins blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Myelodysplastic Syndromes blood MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
In recent years the plasma proteomes of several different myelodysplastic syndrome (MDS) subgroups have been investigated and compared with those of healthy donors. However, the resulting data do not facilitate a direct and statistical comparison of the changes among the different MDS subgroups that would be useful for the selection and proposal of diagnostic biomarker candidates. The aim of this work was to identify plasma protein biomarker candidates for different MDS subgroups by reanalyzing the proteomic data of four MDS subgroups: refractory cytopenia with multilineage dysplasia (RCMD), refractory anemia or refractory anemia with ringed sideroblasts (RA-RARS), refractory anemia with excess blasts subtype 1 (RAEB-1), and refractory anemia with excess blasts subtype 2 (RAEB-2). Reanalysis of a total of 47 MDS patients revealed biomarker candidates, with alpha-2-HS-glycoprotein and leucine-rich alpha-2-glycoprotein as the most promising candidates.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028127
- 003
- CZ-PrNML
- 005
- 20161020111300.0
- 007
- ta
- 008
- 161005s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1155/2015/209745 $2 doi
- 024 7_
- $a 10.1155/2015/209745 $2 doi
- 035 __
- $a (PubMed)26448929
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Majek, Pavel $u Department of Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
- 245 10
- $a Plasma Protein Biomarker Candidates for Myelodysplastic Syndrome Subgroups / $c P. Majek, K. Pecankova, J. Cermak, JE. Dyr,
- 520 9_
- $a In recent years the plasma proteomes of several different myelodysplastic syndrome (MDS) subgroups have been investigated and compared with those of healthy donors. However, the resulting data do not facilitate a direct and statistical comparison of the changes among the different MDS subgroups that would be useful for the selection and proposal of diagnostic biomarker candidates. The aim of this work was to identify plasma protein biomarker candidates for different MDS subgroups by reanalyzing the proteomic data of four MDS subgroups: refractory cytopenia with multilineage dysplasia (RCMD), refractory anemia or refractory anemia with ringed sideroblasts (RA-RARS), refractory anemia with excess blasts subtype 1 (RAEB-1), and refractory anemia with excess blasts subtype 2 (RAEB-2). Reanalysis of a total of 47 MDS patients revealed biomarker candidates, with alpha-2-HS-glycoprotein and leucine-rich alpha-2-glycoprotein as the most promising candidates.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glykoproteiny $x krev $7 D006023
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a myelodysplastické syndromy $x krev $7 D009190
- 650 _2
- $a fetuin A $x metabolismus $7 D060749
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pecankova, Klara $u Department of Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
- 700 1_
- $a Cermak, Jaroslav $u Clinical Department, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
- 700 1_
- $a Dyr, Jan E $u Department of Biochemistry, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic.
- 773 0_
- $w MED00182164 $t BioMed research international $x 2314-6141 $g Roč. 2015, č. - (2015), s. 209745
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26448929 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161020111707 $b ABA008
- 999 __
- $a ok $b bmc $g 1166441 $s 952757
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 2015 $c - $d 209745 $e 20150913 $i 2314-6141 $m BioMed research international $n Biomed Res Int $x MED00182164
- LZP __
- $a Pubmed-20161005